The What, Why and How of Adaptive Clinical Trials
Quanticate explores the rise, the issues, and challenges of Adaptive Clinical Trials and the ways to adapt your study, with examples of oncology study design.
Quanticate explores the rise, the issues, and challenges of Adaptive Clinical Trials and the ways to adapt your study, with examples of oncology study design.
Quanticate analyze whether having a Dose Expansion Phase in Phase I Oncology Trials is beneficial and provides information about Efficacy, Safety, Toxicity and Pharmacokinetics prior to jumping into a Phase II Study
This blog describes the evolution of patient centricity in clinical trials and data collection, and the benefits of working in the biometric industry.
This blog post reviews the Advantages of Parallel Processing on the reporting and analysis of clinical trial data using SAS/Connect. Learn more with Quanticate's programming experts.
This blog post reviews re-randomization tests in equivalence trials and superiority trials and if, when and how to use them.
This blog post reviews the FDA's guidance for Human Gene Therapy (GT) for Hemophilia A & B clinical trials and what is needed to support an accelerated approval approach. Learn More
Different designs used in Phase 1 Clinical Trials suit certain study types to determine the safety, tolerability and pharmacokinetics (PK) of new compounds
This article looks at the evaluation of three methods assessing an early-phase equivalence in biosimilars for Rheumatoid Arthritis treatments.
A survey result on the challenges of pharmacovigilance in early phase clinical trials and solutions to a lack of data, complicated patients and protocol design
Quanticate blogs on the different phases of clinical trials that are classified into 4 phases, with each potentially lasting for several years.